ReviewVirology2013
The papillomavirus major capsid protein L1.
Review in Virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 134 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
134 citing papers in PubMed, 1 synthesis or guideline pooled it, 252 citations in OpenAlex.
- HPV in breast cancer: prevalence and comparison with healthy tissue-a systematic review and meta-analysis.Cancer causes & control : CCC · 2026Pooled it
- The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies.Scientific reports · 2016Trial
- Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression.Journal of immunology (Baltimore, Md. : 1950) · 2014Trial
- Identification and characterization of a novel Taupapillomavirus strain in lymphoid tissue of a stray dog.Virus genes · 2026Article
- Developing Antiviral Vaccines Based on AttenuatedPathogens (Basel, Switzerland) · 2026Review
- Article
- Atomic resolution structure of human papillomavirus bound to heparin.Nature communications · 2026Article
- Identification of Conserved Cross-Reactive B-Cell Epitopes in CPV1 and CPV2 L1 Proteins with Vaccine Potential.Vaccines · 2026Article
- Optimization of cultivation strategies for production of recombinant human papillomavirus type 58 major capsid protein L1 in Hansenula polymorpha.Bioresources and bioprocessing · 2026Article
- Regulation of HPV-16 infection by ubiquitination of the L1 major capsid protein.Journal of virology · 2026Article
- Evolutionary Dynamics of Human Papillomavirus in Thailand: Immunoinformatic Design of a Synergistic L1/L2 Vaccine Candidate.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Integrating Adjuvant HPV Vaccination into Cervical Dysplasia Management After LLETZ/Conization.Journal of clinical medicine · 2026Article
- Mouse Vocal Fold Permeability In Vivo: Effects of Novel Low-Tech Injury and Instillation Methods.The Laryngoscope · 2026Article
- Profiling Human Papillomavirus Lineage-Specific Capsid Antigenicity With Geographically Diverse Natural Infection Antibodies.The Journal of infectious diseases · 2026Article
- Polyanionic Sugars Drastically Affect Assembly of Human Papilloma Virus Virus-Like Particles.ACS infectious diseases · 2026Article
- Aurora kinase B as a therapeutic target in HPV-induced cervical cancer: mechanisms and future perspectives.Frontiers in oncology · 2026Review
- A novel approach to HPV16 VLP construction and production with improved accessibility and particle sorting potential.Frontiers in molecular medicine · 2026Article
- Alternative antigen retention by a gp96-fusion approach induces long-lasting and broad immunity in mice.Nature communications · 2025Article
- Identification and characterization of a novel papillomavirus in thornback skate (Microbial genomics · 2025Article
- Next-generation antiviral peptides: AI-driven design, translational delivery platforms, and future therapeutic directions.Virus research · 2025Review
74 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The elegant icosahedral surface of the papillomavirus virion is formed by a single protein called L1. Recombinant L1 proteins can spontaneously self-assemble into a highly immunogenic structure that closely mimics the natural surface of native papillomavirus virions. This has served as the basis for two highly successful vaccines against cancer-causing human papillomaviruses (HPVs). During the viral life cycle, the capsid must undergo a variety of conformational changes, allowing key functions including the encapsidation of the ~8 kb viral genomic DNA, maturation into a more stable state to survive transit between hosts, mediating attachment to new host cells, and finally releasing the viral DNA into the newly infected host cell. This brief review focuses on conserved sequence and structural features that underlie the functions of this remarkable protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.